Breaking News Instant updates and real-time market news.

MNTA

Momenta

$14.43

0.53 (3.81%)

, ABBV

AbbVie

$83.66

1.12 (1.36%)

16:47
11/06/18
11/06
16:47
11/06/18
16:47

Momenta settles with AbbVie regarding commercializing M923

Momenta Pharmaceuticals (MNTA) announced that it has executed agreements with AbbVie (ABBV) providing license rights for the global launch of M923, Momenta's proposed biosimilar to Humira. Under the terms of the agreements and subject to approval by health regulatory authorities, Momenta may launch M923 in the United States on November 20, 2023 and in Europe upon approval by the European Medicines Agency. Momenta plans to submit a biologics license application for M923 to the FDA in Q4 of 2018 and a marketing authorization application in the European Union in the first half of 2019.

MNTA

Momenta

$14.43

0.53 (3.81%)

ABBV

AbbVie

$83.66

1.12 (1.36%)

  • 07

    Nov

MNTA Momenta
$14.43

0.53 (3.81%)

06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
09/13/18
STFL
09/13/18
INITIATION
Target $40
STFL
Buy
Momenta assumed with a Buy at Stifel
Stifel analyst Derek Archila assumed Momenta with a Buy rating and a price target of $40, saying the stock offers an investment in an "exciting biotech company that has a pipeline with demonstrated proof-of-mechanism". The analyst expects sentiment on Momenta to shift as it "completes its strategic review, ideally sheds costs/potentially monetizes its legacy businesses, and narrows its focus on its proprietary pipeline M281 and M254.
10/11/18
PIPR
10/11/18
NO CHANGE
PIPR
Overweight
Piper says Momenta update underscores safer profile of Argenx's efgartigimod
Piper Jaffray analyst Edward Tenthoff noted that at Momenta's (MNTA) R&D Day the company shared additional safety data for anti-FcRn antibody M281, disclosing that three subjects in the multiple ascending dose cohort of the Phase 1 study experienced CK elevation and terminated dosing. Also, a 25-30% reduction in serum albumin was reported across single and multiple dosing cohorts, said Tenthoff, who added that neither of these events were observed in Argenx's (ARGX) animal or healthy volunteer studies for efgartigimod. The analyst, who believes efgartigimod produces similar activity without compromising safety and sees the company as about two years ahead of Momenta, keeps an Overweight rating and $154 price target on Argenx shares.
11/05/18
PIPR
11/05/18
INITIATION
Target $35
PIPR
Overweight
Momenta initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Momenta Pharmaceuticals with an Overweight rating and $35 price target. The company offers a "rare" biotech investment opportunity as its stock is "super cheap" and its anti-FcRn therapies could be game changing for treating auto-immune diseases, Brill tells investors in a research note. Momenta's proprietary pipeline has "major blockbuster potential and is underappreciated by investors," says the analyst.
ABBV AbbVie
$83.66

1.12 (1.36%)

10/25/18
BMOC
10/25/18
NO CHANGE
Target $192
BMOC
Outperform
Vertex price target lowered to $192 from $204 at BMO Capital
BMO Capital analyst Do Kim lowered his price target on Vertex (VRTX) to $192, saying its in-line Q3 results may be overshadowed by the AbbVie (ABBV) decision to license rights to Galapagos (GLPG) cystic fibrosis program, since the expectation was for the collaboration to dissolve. The analyst adds that while the Galapagos interim data did not make competitive inroads on Vertex therapies, he is still lowering the the FY19 EPS view for the latter to $4.43 from $5.13 on slow ex-U.S. growth amid reimbursement challenges and higher operating expenses. Longer term, Kim keeps his Outperform rating on Vertex.
10/30/18
NOMU
10/30/18
NO CHANGE
Target $140
NOMU
Buy
Galapagos price target raised to $140 from $124 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Galapagos NV to $140 following last week's Q3 results and the sale of its partnered-cystic fibrosis program back to AbbVie (ABBV) for $45M upfront and $200M in milestones. The analyst views the upfront payments as upside to expectations and keeps a Buy rating on Galapagos shares.
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
AbbVie Q3 results do not convince Piper Jaffray to get off sidelines
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating on AbbVie after the company's Q3 earnings results, which Raymond noted were better than expected. However, the analyst was cautious given management's indication of growing headwinds, which he believes "portend a meaningful downward revision to FY19 consensus." Additionally, Raymond sees AbbVie "married to the prospects of Humira," which he believes now faces international headwinds competing with four biosimilars.
11/06/18
ARGS
11/06/18
NO CHANGE
Target $115
ARGS
Buy
AbbVie price target lowered to $115 from $130 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $115 to reflect the competitive environment for its Humira sales from biosimilars in Europe, but also kept his Buy rating and raised his FY18 EPS view by 9c to $7.91 and FY19 by 12c to $9.00. The analyst says Humira should continue to post "solid growth" in the U.S. markets, and also cites the prospects of its Imbruvica, Venclexta Orilissa and hepatitis C drugs along with its remaining product pipeline. Toung contends that the "incremental sales of new faster-growing products can more than offset the expected decline in overseas sales of Humira".

TODAY'S FREE FLY STORIES

GLD

SPDR Gold Shares

$125.06

-1.41 (-1.11%)

19:10
02/21/19
02/21
19:10
02/21/19
19:10
Hot Stocks
SPDR Gold Shares holdings fall to 789.51MT from 794.50MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOG

Extraction Oil & Gas

$3.81

-0.1 (-2.56%)

, BOOM

DMC Global

$35.37

0.04 (0.11%)

19:05
02/21/19
02/21
19:05
02/21/19
19:05
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

XOG

Extraction Oil & Gas

$3.81

-0.1 (-2.56%)

BOOM

DMC Global

$35.37

0.04 (0.11%)

TTD

Trade Desk

$150.18

0.07 (0.05%)

CATM

Cardtronics

$26.06

-0.98 (-3.62%)

Z

Zillow

$35.03

0.22 (0.63%)

OLED

Universal Display

$118.31

-0.57 (-0.48%)

BYD

Boyd Gaming

$28.28

-0.11 (-0.39%)

FIX

Comfort Systems USA

$51.96

0.32 (0.62%)

CYTK

Cytokinetics

$7.20

-0.14 (-1.91%)

ROKU

Roku

$51.47

-2.16 (-4.03%)

TXMD

TherapeuticsMD

$5.10

-0.36 (-6.59%)

BIDU

Baidu

$171.72

0.64 (0.37%)

CWST

Casella Waste

$33.55

-1.47 (-4.20%)

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

DAIO

Data I/O

$5.94

-0.04 (-0.67%)

HPE

HP Enterprise

$16.22

0.16 (1.00%)

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

ASPN

Aspen Aerogels

$3.60

0.03 (0.84%)

DBX

Dropbox

$25.58

0.1 (0.39%)

MDRX

Allscripts

$11.93

-0.21 (-1.73%)

AAOI

Applied Optoelectronics

$14.62

(0.00%)

CASA

Casa Systems

$11.96

-0.02 (-0.17%)

UCTT

Ultra Clean

$12.59

-0.26 (-2.02%)

BJRI

BJ's Restaurants

$51.97

0.75 (1.46%)

BMRN

BioMarin

$88.80

-1.82 (-2.01%)

TGH

Textainer

$13.05

-0.06 (-0.46%)

APPN

Appian

$38.73

0.41 (1.07%)

INFN

Infinera

$4.87

-0.02 (-0.41%)

NVRO

Nevro

$47.27

-1.12 (-2.31%)

FSLR

First Solar

$51.91

0.23 (0.45%)

CENX

Century Aluminum

$9.30

0.12 (1.31%)

UEIC

Universal Electronics

$29.34

0.36 (1.24%)

RMAX

RE/MAX Holdings

$40.34

-0.2 (-0.49%)

STAA

STAAR Surgical

$36.86

0.17 (0.46%)

SLRC

Solar Capital

$21.27

0.34 (1.62%)

IQ

iQIYI

$22.76

0.17 (0.75%)

EHTH

eHealth

$65.58

-0.28 (-0.43%)

PE

Parsley Energy

$17.93

-0.595 (-3.21%)

EXAS

Exact Sciences

$83.30

-0.3 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 11

    Mar

  • 11

    Mar

  • 13

    Mar

  • 13

    Mar

  • 13

    Mar

  • 20

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 18

    May

  • 22

    May

GM

General Motors

$39.63

-0.33 (-0.83%)

18:54
02/21/19
02/21
18:54
02/21/19
18:54
Periodicals
GM CEO will not appear in front of Canada lawmakers over closure, Reuters says »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

CXO

Concho Resources

$103.69

-8.68 (-7.72%)

18:37
02/21/19
02/21
18:37
02/21/19
18:37
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 28

    May

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

18:37
02/21/19
02/21
18:37
02/21/19
18:37
Hot Stocks
Kraft Heinz confirms quarterly dividend cut to 40c from 62.5c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

18:32
02/21/19
02/21
18:32
02/21/19
18:32
Hot Stocks
Kraft Heinz says has taken 'remedial measures' on procurement issues »

Says write down reflected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:25
02/21/19
02/21
18:25
02/21/19
18:25
Hot Stocks
Breaking Hot Stocks news story on Caesars »

Caesars: Las Vegas FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

RARE

Ultragenyx

$58.16

-2.33 (-3.85%)

18:20
02/21/19
02/21
18:20
02/21/19
18:20
Initiation
Ultragenyx initiated  »

Ultragenyx resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, CPB

Campbell Soup

$35.44

0.26 (0.74%)

18:13
02/21/19
02/21
18:13
02/21/19
18:13
Periodicals
Third Point says confident in Nestle CEO's leadership, Reuters reports »

Third Point told…

NSRGY

Nestle

$0.00

(0.00%)

CPB

Campbell Soup

$35.44

0.26 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    May

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

18:11
02/21/19
02/21
18:11
02/21/19
18:11
Hot Stocks
Breaking Hot Stocks news story on Stamps.com »

Stamps.com drops 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

STMP

Stamps.com

$198.08

-4.03 (-1.99%)

18:09
02/21/19
02/21
18:09
02/21/19
18:09
Hot Stocks
Stamps.com to discontinue partnership with USPS »

On its Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:08
02/21/19
02/21
18:08
02/21/19
18:08
Hot Stocks
Caesars expect modest Las Vegas revenue growth in Q1 »

Sees adverse weather…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

18:06
02/21/19
02/21
18:06
02/21/19
18:06
Hot Stocks
Breaking Hot Stocks news story on Caesars »

Caesars says will not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LNT

Alliant Energy

$45.63

0.45 (1.00%)

18:03
02/21/19
02/21
18:03
02/21/19
18:03
Earnings
Breaking Earnings news story on Alliant Energy »

Alliant Energy sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

LNT

Alliant Energy

$45.63

0.45 (1.00%)

18:02
02/21/19
02/21
18:02
02/21/19
18:02
Earnings
Alliant Energy reports Q4 EPS 36c, conseensus 35c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BVN

Buenaventura

$16.53

-0.37 (-2.19%)

17:59
02/21/19
02/21
17:59
02/21/19
17:59
Earnings
Buenaventura reports Q4 EPS (29c), consensus 5c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 12

    Mar

  • 12

    Mar

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:58
02/21/19
02/21
17:58
02/21/19
17:58
Hot Stocks
Kraft Heinz says expects to face profit headwinds in 2019 »

Says: Expects EBITDA down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

GABC

German American Bancorp

$31.59

(0.00%)

, CZFC

Citizens First

$23.30

1.87 (8.73%)

17:56
02/21/19
02/21
17:56
02/21/19
17:56
Hot Stocks
German American, Citizens First announce merger pact »

German American Bancorp,…

GABC

German American Bancorp

$31.59

(0.00%)

CZFC

Citizens First

$23.30

1.87 (8.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$291.18

-11.33 (-3.75%)

17:56
02/21/19
02/21
17:56
02/21/19
17:56
Periodicals
Lucid Motors is 'working' on an all electric SUV, Verge says »

Electric vehicle startup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

CZR

Caesars

$9.42

-0.21 (-2.18%)

17:54
02/21/19
02/21
17:54
02/21/19
17:54
Hot Stocks
Caesars sees FY19 same-store capex $375M-$450M »

Sees FY19 development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

PBA

Pembina Pipeline

$36.44

-0.235 (-0.64%)

17:54
02/21/19
02/21
17:54
02/21/19
17:54
Earnings
Pembina Pipeline reports Q4 EPS C$0.66 vs C$0.83 last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:53
02/21/19
02/21
17:53
02/21/19
17:53
Hot Stocks
Kraft Heinz continues to fall, now down 16.5% to $40.25 »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CZR

Caesars

$9.42

-0.21 (-2.18%)

17:52
02/21/19
02/21
17:52
02/21/19
17:52
Hot Stocks
Caesars says in discussions with Carl Icahn after his disclosed stake »

Comments from Q4 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HRS

Harris

$164.55

-0.62 (-0.38%)

17:48
02/21/19
02/21
17:48
02/21/19
17:48
Hot Stocks
Harris awarded $168.8M Navy contract modification »

Harris has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$48.19

-0.05 (-0.10%)

17:45
02/21/19
02/21
17:45
02/21/19
17:45
Hot Stocks
Kraft Heinz to cut quarterly dividend to 40c from 62.5c per share »

Says: Higher supply chain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.